.Pharmacolibrary.Drugs.ATC.C.C08CA06

Information

Nimodipine is a dihydropyridine calcium channel blocker used primarily to reduce the incidence and severity of neurological deficits arising from cerebral vasospasm following subarachnoid hemorrhage. Approved and used today mainly for this indication.

Pharmacokinetics

Pharmacokinetic parameters in healthy adult volunteers after oral administration.

References

1. Mahmoud, SH, et al., & Isse, FA (2020). Nimodipine Pharmacokinetic Variability in Various Patient Populations. Drugs in R&D 20(4) 307–318. DOI:10.1007/s40268-020-00322-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32902829

2. Kumana, CR, et al., & Lauder, IJ (1993). Investigation of nimodipine pharmacokinetics in Chinese patients with acute subarachnoid haemorrhage. European journal of clinical pharmacology 45(4) 363–366. DOI:10.1007/BF00265956 PUBMED:https://pubmed.ncbi.nlm.nih.gov/8299671

3. Terziivanov, D, et al., & Mück, W (1999). Pharmacokinetic variability of nimodipine disposition after single and multiple oral dosing to hypertensive renal failure patients: parametric and nonparametric population analysis. International journal of clinical pharmacology and therapeutics 37(8) 404–412. PUBMED:https://pubmed.ncbi.nlm.nih.gov/10475143

Revisions

• 06/2025 initial generated model